Kala Pharmaceuticals
OverviewSuggest Edit
Kala Pharmaceuticals is a clinical-stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both the front and back of the eye. It utilizes its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations. The company also researches a small molecule receptor tyrosine kinase inhibitor (RTKi) program as a potential topical treatment of wet age-related macular degeneration (AMD).
| Type | Public | |
| Founded | 2009 | |
| HQ | Watertown, MA, US | Map |
| Website | kalarx.com | |
| Employee Ratings | More | |
| Overall Culture | A+ | More |
Recent NewsAll News
- Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021
- Thinking about buying stock in Marqeta, Lexicon Pharmaceuticals, Kala Pharmaceuticals, Owlet, or New Oriental Education?
- Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Kala Pharmaceuticals to Present at Upcoming Investor Conferences in August
Key People/Management at Kala Pharmaceuticals
Mark Iwicki
Chairman and Chief Executive Officer
Kim Brazzell
Chief Medical Officer
Hongming Chen
Chief Scientific Officer
Mary Reumuth
Chief Financial Officer
Todd Bazemore
Chief Operating Officer
Eric L. Trachtenberg
General Counsel and Chief Compliance Officer
Kala Pharmaceuticals Office Locations
Kala Pharmaceuticals has an office in Watertown
Watertown, MA, US (HQ)
490 Arsenal Way, Suite 120
Kala Pharmaceuticals Financials and Metrics
Kala Pharmaceuticals Revenue
Kala Pharmaceuticals's revenue was reported to be $45 k in FY, 2015
| USD | |
|---|---|
Net income (FY, 2016) | (33.2m) |
EBIT (FY, 2016) | (32.7m) |
Market capitalization (14-Sept-2021) | 197.2m |
Closing stock price (14-Sept-2021) | 3.0 |
Cash (31-Dec-2016) | 42.5m |
Kala Pharmaceuticals's current market capitalization is $197.2 m.
- Source: SEC Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Revenue | 45.0k | |
General and administrative expense | 4.6m | 7.6m |
R&D expense | 11.4m | 25.0m |
Operating expense total | 16.0m | 32.7m |
- Source: SEC Filings, SEC Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash | 5.8m | 42.5m |
Current Assets | 7.6m | 45.6m |
PP&E | 738.0k | 594.0k |
Total Assets | 8.4m | 46.3m |
- Source: SEC Filings, SEC Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Net Income | (16.7m) | (33.2m) |
Depreciation and Amortization | 330.0k | 297.0k |
Accounts Payable | 911.0 | (343.0) |
Cash From Operating Activities | (15.1m) | (27.3m) |
- Source: SEC Filings, SEC Filings
Kala Pharmaceuticals Operating Metrics
Show all operating metricsKala Pharmaceuticals Cybersecurity Score
Kala Pharmaceuticals Online and Social Media Presence
Kala Pharmaceuticals's Trends
Kala Pharmaceuticals Company Culture
Overall Culture
A+
94/100
CEO Rating
A+
100/100
Compensation
A+
100/100
Kala Pharmaceuticals News and Updates
September 07, 2021
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021
WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate …
August 30, 2021
Thinking about buying stock in Marqeta, Lexicon Pharmaceuticals, Kala Pharmaceuticals, Owlet, or New Oriental Education?
NEW YORK, Aug. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MQ, LXRX, KALA, OWLT, and EDU. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
August 05, 2021
Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
-- EYSUVIS Prescriptions Increased by 93% Compared to First Quarter of 2021 ---- Further Expanded Commercial Coverage for EYSUVIS to More Than 96 Million Lives ---- Achieved $3.1 Million in Net Revenue in Second Quarter of 2021 ---- Conference Call and Webcast at 8:00 a.m. ET -- WATERTOWN, Mass., Au…
August 04, 2021
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in August
WATERTOWN, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following v…
July 29, 2021
Kala Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call
WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report second quarter 2021 financial r…
Kala Pharmaceuticals Blogs
June 03, 2021
Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx
-- EYSUVIS Added to OptumRx Commercial Formularies Effective May 21, 2021 -- -- Expands Total Commercial Coverage for EYSUVIS to More Than 88 Million Lives -- WATERTOWN, Mass. --(BUSINESS WIRE)--Jun. 3, 2021-- Kala Pharmaceuticals, Inc. , (NASDAQ:KALA), a biopharmaceutical company focused on the
May 27, 2021
Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference
WATERTOWN, Mass. --(BUSINESS WIRE)--May 27, 2021-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2021 Virtual
May 06, 2021
Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference
Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference
Content Import
Thu, 05/06/2021 - 08:01
Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference
May 6, 2021 at 8:00 AM EDT
This release is a backfill from a News…
May 05, 2021
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
Content Import
Wed, 05/05/2021 - 07:04
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 5, 2021 at 7:01 AM EDT
Th…
April 28, 2021
Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call
WATERTOWN, Mass. --(BUSINESS WIRE)--Apr. 28, 2021-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2021 financial
March 16, 2021
Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna
Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna
Content Import
Tue, 03/16/2021 - 08:01
Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna
March 16, 2021 at 8:00 AM EDT
This release is a backfill from a News Wire
…
Kala Pharmaceuticals Frequently Asked Questions
When was Kala Pharmaceuticals founded?
Kala Pharmaceuticals was founded in 2009.
Who are Kala Pharmaceuticals key executives?
Kala Pharmaceuticals's key executives are Mark Iwicki, Kim Brazzell and Hongming Chen.
How many employees does Kala Pharmaceuticals have?
Kala Pharmaceuticals has 188 employees.
Who are Kala Pharmaceuticals competitors?
Competitors of Kala Pharmaceuticals include EMS Pharma, Genentech and UCB.
Where is Kala Pharmaceuticals headquarters?
Kala Pharmaceuticals headquarters is located at 490 Arsenal Way, Suite 120, Watertown.
Where are Kala Pharmaceuticals offices?
Kala Pharmaceuticals has an office in Watertown.
How many offices does Kala Pharmaceuticals have?
Kala Pharmaceuticals has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies